IDEAYA Biosciences
IDYAIDYA · Stock Price
Historical price data
Overview
IDEAYA Biosciences is a precision medicine oncology company founded in 2016 with a mission to develop transformative, biomarker-selected cancer therapies. It has established itself as a leader in the field of synthetic lethality, building a robust clinical-stage pipeline through internal discovery and strategic collaborations with major pharmaceutical partners like GSK, Pfizer, and Gilead. The company's strategy focuses on exploiting specific genetic vulnerabilities in cancer cells to achieve a therapeutic window, with its most advanced programs targeting MTAP-deleted solid tumors, GNAQ/GNA11-mutant cancers, and homologous recombination deficient tumors.
Technology Platform
An integrated precision medicine platform centered on synthetic lethality, combining target & biomarker discovery, translational biology, and small molecule/protein degrader therapeutics to develop drugs for genetically defined cancer populations.
Pipeline
8| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Darovasertib | Uveal Melanoma | Phase 3 | |
| IDE196 + Crizotinib + Pembrolizumab + Ipilimumab + Nivolumab... | Metastatic Uveal Melanoma | Phase 2/3 | |
| Darovasertib | Uveal Melanoma | Phase 2 | |
| IDE849 + durvalumab + IDE161 | Small-cell Lung Cancer | Phase 1/2 | |
| IDE196 + Binimetinib + Crizotinib | Metastatic Uveal Melanoma | Phase 1/2 |